Pfizer's $43B Seagen deal strengthens its oncology portfolio, offsets patent cliffs, and offers 70%+ upside potential. See ...

Pfizer is positioning for a potential long-term rebound following a steep post-COVID revenue decline and a drop of over 50% ...

The PD-1xVEGF dealmaking wave that has captivated Western pharma companies is now surging within China. | Sino Biopharm said ...

Pfizer is on the brink of a major rebound, transitioning focus to oncology and potential blockbuster drugs after a sharp drop in COVID-related revenues. Pfizer’s stock has plummeted over 50% in the ...

Pfizer Inc. has completed the previously announced global, ex-China, licensing agreement with 3SBio Inc., which grants Pfizer exclusive rights for the development, manufacturing and commercialization ...

China, licensing agreement with 3SBio, granting Pfizer exclusive rights for the development, manufacturing and commercialization of 3SBio’s SSGJ-707, a bispecific antibody targeting PD-1 and VEGF ...

Pfizer (PFE) stock in focus as the company with Astellas Pharma (ALPMF) (ALPMY) announce a Phase 3 trial win for their prostate cancer drug Xtandi. Read more here.

Pfizer's hemophilia therapy, Hympavzi, met the main goal of a late-stage study in patients with certain types of antibodies, the U.S. drugmaker said on Thursday.

NEW YORK-- (BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 third-quarter 2025 dividend on the company’s common stock, payable September 2 ...

AbbVie has placed a high price on that potential, coughing up $700 million for a phase 1 candidate and offering up to $1.225 ...

Pfizer Inc. has initiated a new clinical study titled A Phase 1, Randomized, Double Blind, Sponsor-Open, Placebo-Controlled, Single Dose Escalation Study to Evaluate the Safety, Tolerability, and ...

Successful trial data in a subset of hemophilia patients has set up Pfizer’s Hympavzi, which was approved eight months ago, for a label expansion ...